MCDA Hemlibra® in haemophilia A without inhibitors

//MCDA Hemlibra® in haemophilia A without inhibitors

MCDA Hemlibra® in haemophilia A without inhibitors

Determining the value contribution of emicizumab (hemlibra®) for the prophylaxis of haemophilia A patients without inhibitors in Spain by multi-criteria decision analysis (MCDA)

Avaliable at: https://economiadelasalud.com/tag/haemophilia-a/

2020-09-23T17:26:42+00:00May 18th, 2020|Articles|

Leave A Comment

This website uses cookies so that you have the best user experience. If you continue browsing you are giving your consent for the acceptance of the aforementioned cookies and the acceptance of our cookies policy, Click on the link for more information. ACEPTAR

Aviso de cookies